Who We Are
We choose to adopt fresh perspectives, concentrating on understanding why cancer therapies falter over time rather than pursue incremental treatment improvements. In this pursuit, we are propelled by the realm of possibilities and the chance to significantly transform the lives of cancer patients.
Where does our strategy lead? Back to biology. Back to studying the forest and not just a few trees. Back to comprehending the reliance and interdependence of biological targets to design molecules that effectively block the escape routes exploited by cancer to resist treatment. Our preclinical data highlights the efficacy of efficiently inhibiting the appropriate combination of targets, rather than solely prioritizing higher selectivity and potency directed at a single target. The outcome is superior and enduring single-agent anti-cancer activity, as well as superior and more enduring anti-cancer activity when combined with other agents.
Leading with innovation
Leadership Team
-
Judith Leopold, PhD
CHIEF SCIENTIFIC OFFICER
An internationally recognized expert in kinase signaling and co-inventor of the technology, Dr. Leopold pioneered the MEK inhibitor field. She is Program Co-Leader of Developmental Therapeutics at Rogel Cancer Center and was previously Executive Director of Mechanistic & Target Biology at Pfizer Global R&D.
-
Christopher Whitehead, PhD, MBA
CHIEF OPERATING OFFICER
An expert in computational medicinal chemistry and co-inventor of the technology, Dr. Whitehead is a co-founder of several pharmaceutical start-ups. He was previously Director of Research and Strategy at ProNAi Therapeutics, and a Computer-Assisted Drug Designer at Pfizer Global R&D.
-
Danny Cunagin
CHIEF EXECUTIVE OFFICER
With over 30 years of experience as a seasoned entrepreneur, Mr. Cunagin has spearheaded the launch, development, and successful sale of multiple Biotech, Medtech, and Healthcare IT companies. These endeavors not only yield substantial returns for investors but also create a profound impact on people's lives.